8
|
Takagi M, Yoshida M, Nemoto Y, Tamaichi H, Tsuchida R, Seki M, Uryu K, Nishii R, Miyamoto S, Saito M, Hanada R, Kaneko H, Miyano S, Kataoka K, Yoshida K, Ohira M, Hayashi Y, Nakagawara A, Ogawa S, Mizutani S, Takita J. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor. J Natl Cancer Inst 2017; 109:4096548. [PMID: 29059438 DOI: 10.1093/jnci/djx062] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Accepted: 03/13/2017] [Indexed: 11/14/2022] Open
Abstract
Background Neuroblastoma (NB) is the most common solid tumor found in children, and deletions within the 11q region are observed in 11% to 48% of these tumors. Notably, such tumors are associated with poor prognosis; however, little is known regarding the molecular targets located in 11q. Methods Genomic alterations of ATM , DNA damage response (DDR)-associated genes located in 11q ( MRE11A, H2AFX , and CHEK1 ), and BRCA1, BARD1, CHEK2, MDM2 , and TP53 were investigated in 45 NB-derived cell lines and 237 fresh tumor samples. PARP (poly [ADP-ribose] polymerase) inhibitor sensitivity of NB was investigated in in vitro and invivo xenograft models. All statistical tests were two-sided. Results Among 237 fresh tumor samples, ATM, MRE11A, H2AFX , and/or CHEK1 loss or imbalance in 11q was detected in 20.7% of NBs, 89.8% of which were stage III or IV. An additional 7.2% contained ATM rare single nucleotide variants (SNVs). Rare SNVs in DDR-associated genes other than ATM were detected in 26.4% and were mutually exclusive. Overall, samples with SNVs and/or copy number alterations in these genes accounted for 48.4%. ATM-defective cells are known to exhibit dysfunctions in homologous recombination repair, suggesting a potential for synthetic lethality by PARP inhibition. Indeed, 83.3% NB-derived cell lines exhibited sensitivity to PARP inhibition. In addition, NB growth was markedly attenuated in the xenograft group receiving PARP inhibitors (sham-treated vs olaprib-treated group; mean [SD] tumor volume of sham-treated vs olaprib-treated groups = 7377 [1451] m 3 vs 298 [312] m 3 , P = .001, n = 4). Conclusions Genomic alterations of DDR-associated genes including ATM, which regulates homologous recombination repair, were observed in almost half of NBs, suggesting that synthetic lethality could be induced by treatment with a PARP inhibitor. Indeed, DDR-defective NB cell lines were sensitive to PARP inhibitors. Thus, PARP inhibitors represent candidate NB therapeutics.
Collapse
Affiliation(s)
- Masatoshi Takagi
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Misa Yoshida
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Yoshino Nemoto
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Hiroyuki Tamaichi
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Rika Tsuchida
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Masafumi Seki
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Kumiko Uryu
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Rina Nishii
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Satoshi Miyamoto
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Masahiro Saito
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Ryoji Hanada
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Hideo Kaneko
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Satoru Miyano
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Keisuke Kataoka
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Kenichi Yoshida
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Miki Ohira
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Yasuhide Hayashi
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Akira Nakagawara
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Seishi Ogawa
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Shuki Mizutani
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Junko Takita
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| |
Collapse
|
11
|
Inoue S, Li WY, Tseng A, Beerman I, Elia AJ, Bendall SC, Lemonnier F, Kron KJ, Cescon DW, Hao Z, Lind EF, Takayama N, Planello AC, Shen SY, Shih AH, Larsen DM, Li Q, Snow BE, Wakeham A, Haight J, Gorrini C, Bassi C, Thu KL, Murakami K, Elford AR, Ueda T, Straley K, Yen KE, Melino G, Cimmino L, Aifantis I, Levine RL, De Carvalho DD, Lupien M, Rossi DJ, Nolan GP, Cairns RA, Mak TW. Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. Cancer Cell 2016; 30:337-348. [PMID: 27424808 PMCID: PMC5022794 DOI: 10.1016/j.ccell.2016.05.018] [Citation(s) in RCA: 146] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Revised: 04/01/2016] [Accepted: 05/31/2016] [Indexed: 12/20/2022]
Abstract
Mutations in the isocitrate dehydrogenase-1 gene (IDH1) are common drivers of acute myeloid leukemia (AML) but their mechanism is not fully understood. It is thought that IDH1 mutants act by inhibiting TET2 to alter DNA methylation, but there are significant unexplained clinical differences between IDH1- and TET2-mutant diseases. We have discovered that mice expressing endogenous mutant IDH1 have reduced numbers of hematopoietic stem cells (HSCs), in contrast to Tet2 knockout (TET2-KO) mice. Mutant IDH1 downregulates the DNA damage (DD) sensor ATM by altering histone methylation, leading to impaired DNA repair, increased sensitivity to DD, and reduced HSC self-renewal, independent of TET2. ATM expression is also decreased in human IDH1-mutated AML. These findings may have implications for treatment of IDH-mutant leukemia.
Collapse
Affiliation(s)
- Satoshi Inoue
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Wanda Y Li
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Alan Tseng
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada
| | - Isabel Beerman
- Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 00133, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA
| | - Andrew J Elia
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Sean C Bendall
- Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - François Lemonnier
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Ken J Kron
- The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada
| | - David W Cescon
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Zhenyue Hao
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Evan F Lind
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Naoya Takayama
- The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Aline C Planello
- The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada; Department of Morphology, Piracicaba Dental School, UNICAMP, Piracicaba, SP 13414-903, Brazil
| | - Shu Yi Shen
- The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada
| | - Alan H Shih
- Human Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | | | - Qinxi Li
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Bryan E Snow
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Andrew Wakeham
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Jillian Haight
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Chiara Gorrini
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Christian Bassi
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Kelsie L Thu
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Kiichi Murakami
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Alisha R Elford
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Takeshi Ueda
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; Department of Disease Model Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan
| | | | | | - Gerry Melino
- Medical Research Council, Toxicology Unit, Leicester LE1 9HN, UK; Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome 00133, Italy
| | - Luisa Cimmino
- Department of Pathology, Howard Hughes Medical Institute, New York University School of Medicine, New York, NY 10016, USA
| | - Iannis Aifantis
- Department of Pathology, Howard Hughes Medical Institute, New York University School of Medicine, New York, NY 10016, USA
| | - Ross L Levine
- Human Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Daniel D De Carvalho
- The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada
| | - Mathieu Lupien
- The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada
| | - Derrick J Rossi
- Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 00133, USA
| | - Garry P Nolan
- The Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Rob A Cairns
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Tak W Mak
- The Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto, ON M5G 2C1, Canada; The Princess Margaret Cancer Centre and Ontario Cancer Institute, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.
| |
Collapse
|